Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report) traded up 3.2% during trading on Monday . The company traded as high as $3.54 and last traded at $3.54. 256,519 shares were traded during trading, a decline of 29% from the average session volume of 361,916 shares. The stock had previously closed at $3.43.
Atea Pharmaceuticals Stock Up 0.8 %
The company has a market cap of $325.93 million, a PE ratio of -1.97 and a beta of 0.18. The firm’s fifty day simple moving average is $3.59 and its 200-day simple moving average is $3.77.
Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.14). On average, analysts predict that Atea Pharmaceuticals, Inc. will post -2.79 earnings per share for the current year.
Insider Buying and Selling at Atea Pharmaceuticals
Hedge Funds Weigh In On Atea Pharmaceuticals
A number of institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its position in shares of Atea Pharmaceuticals by 67.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 16,179 shares of the company’s stock valued at $65,000 after buying an additional 6,526 shares during the last quarter. SG Americas Securities LLC raised its position in shares of Atea Pharmaceuticals by 23.3% in the fourth quarter. SG Americas Securities LLC now owns 42,521 shares of the company’s stock valued at $130,000 after buying an additional 8,024 shares during the last quarter. Sunpointe LLC acquired a new position in shares of Atea Pharmaceuticals in the fourth quarter valued at approximately $36,000. Price T Rowe Associates Inc. MD raised its position in shares of Atea Pharmaceuticals by 21.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 67,137 shares of the company’s stock valued at $272,000 after buying an additional 11,968 shares during the last quarter. Finally, RPO LLC acquired a new position in shares of Atea Pharmaceuticals in the fourth quarter valued at approximately $39,000. Institutional investors and hedge funds own 86.67% of the company’s stock.
Atea Pharmaceuticals Company Profile
Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.
Featured Articles
- Five stocks we like better than Atea Pharmaceuticals
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- Real Estate Stock Signals a Boom in Manufacturing Activity
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- This Medical Giant’s Stock Rebounds: A 15% Upside Is the Minimum
- Insider Trades May Not Tell You What You Think
- Financial Giant’s Shares Soar on EPS Beat and Record Asset Levels
Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.